ArticleScientific reports2026
Platelet count has a U-shaped association with all-cause mortality in COPD patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Identifying reliable prognostic markers is crucial for the effective management of chronic obstructive pulmonary disease (COPD). The platelet count has emerged as a potential inflammatory marker associated with clinical outcomes. The aim of this study was to investigate the relationships of the platelet count with all-cause mortality and readmission rates among patients with acute exacerbations of COPD (AECOPD). Patients who were diagnosed with AECOPD between January 2019 and December 2023 at our institution were included. The platelet count was recorded on admission. The primary outcome was all-cause mortality. The secondary outcomes included readmission for AECOPD and a composite endpoint of readmission and mortality. Multivariate Cox proportional hazards models were constructed to examine the associations between the study endpoints and platelet counts categorized as low, normal, and high (< 150, ≥ 150 to < 300, and ≥ 300 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.